Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pasithea Therapeutics Corp ( (KTTA) ) has shared an update.
Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004, showing clinical activity and a favorable safety profile in patients with advanced solid tumors driven by MAPK pathway alterations. The trials demonstrated partial responses and stable disease in patients, with a disease control rate of 71.4% among those with BRAF-mutated tumors. The drug was well-tolerated, with no dose-limiting toxicities and only mild adverse events. Additionally, the ALS Association awarded a grant to study PAS-004 in ALS patients, indicating potential broader applications for the drug.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a clinical-stage biotechnology company focused on the development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. The company is engaged in research and development for treating RASopathies, MAPK pathway-driven tumors, and other diseases, with ongoing Phase 1 trials in advanced cancer patients and NF1-associated plexiform neurofibromas.
Average Trading Volume: 1,325,153
Technical Sentiment Signal: Sell
Current Market Cap: $3.16M
For an in-depth examination of KTTA stock, go to TipRanks’ Overview page.